Accounting for intensity variation in image analysis of large-scale multiplexed clinical trial datasets

Competing Interest Statement

DNC has participated in advisory boards for MSD and has received research funding on behalf of the TransSCOT consortium from HalioDx for analyses independent of this study. VHK has served as an invited speaker on behalf of Indica Labs and Sharing Progress in Cancer Care (SPCC), is on an advisory board of Takeda and has received project-based research funding from The Image Analysis Group and Roche outside of the submitted work. All other authors declare no competing interests.

Funding Statement

The SCOT trial was funded by the Medical Research Council (transferred to NETSCC - Efficacy and Mechanism Evaluation) (Grant Ref: G0601705), the NIHR Health Technology Assessment Programme (Grant Ref: 14/140/84), Cancer Research UK (CRUK) Core Clinical Trials Unit Glasgow Funding (Funding Ref: C6716/A9894), and the Swedish Cancer Society. The TransSCOT sample collection was funded by a CRUK Clinical Trials Awards and Advisory Committee - Sample Collection (Grant Ref: C6716/A13941). The QUASAR2 trial was funded by an unrestricted educational grant to DJK from Roche. This study was funded by the Oxford NIHR Comprehensive Biomedical Research Centre, a CRUK Advanced Clinician Scientist Fellowship (Ref: C26642/A27963) to DNC, a CRUK award (Ref: A25142) to the CRUK Glasgow Centre and core funding to VHK by the University of Zurich. VHK acknowledges funding by the Promedica Foundation (Ref: F-87701-41-01). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethical approval for patient recruitment and sample collection in the SCOT and QUASAR 2 trial was obtained centrally and at all recruiting centres (REC reference number 07/S0703/136 and 04/MRE/11/18). Ethical approval for anonymised tumour molecular analysis was granted by Oxfordshire Research Ethics Committee B (REC 05\Q1605\66).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes